NCT01728402
Pathogenesis of Hematologic Malignancies
Enrolling by Invitation
Not specifiedAges 1+ObservationalOHSU Knight Cancer InstituteInvestigator-initiated
~5,000 participants
Updated 2026-02-17 on ClinicalTrials.gov
What's tested:blood draw, bone marrow procedure, or tissue biopsy
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Identify and determine the frequency of mutations causing aberrant signaling pathway function in patients with acute leukemias (AL), lymphoproliferative disorders (LPD), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN)
Measured over After laboratory analyses are complete. Lab samples are collected at the time of a scheduled blood draw, bone marrow procedure, tissue biopsy, or other visit for usual medical care
Conditions
Where it's being run
1 sites across 1 statesOregon1
Study leadership
- Cristina Tognon, PhD · PRINCIPAL_INVESTIGATOR · OHSU Knight Cancer Institute
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Suspected or confirmed diagnosis of AL, LPD, MDS, or MPD
Male or female of all ages
Willing and able to sign informed consent
Willing guardian consent for participants under 18 years of age
Exclusion
No suspected or confirmed diagnosis of acute leukemias (AL), lymphoproliferative disorders (LPD), myelodysplastic syndromes (MDS), or myeloproliferative diseases (MPD)
What this trial measures
- Identify and determine the frequency of mutations causing aberrant signaling pathway function in patients with acute leukemias (AL), lymphoproliferative disorders (LPD), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPN)After laboratory analyses are complete. Lab samples are collected at the time of a scheduled blood draw, bone marrow procedure, tissue biopsy, or other visit for usual medical care
Integrated functional genomics studies (whole genome sequencing, RNAi, proteomics, drug sensitivity, expression profiling) will be used to identify aberrant signaling pathways that contribute to the formation of hematologic malignancies.